Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.39 |
| ▸ | BID | P55957 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059332 | 0.87 | BCL2A1 (0.38) | CTSDACHEBCHEBCL2A1 | |
| SCHEMBL6922324 | 0.86 | L3MBTL1 (0.39) | L3MBTL1ACHEBCHELMNA | |
| SCHEMBL12059331 | 0.85 | BCL2A1 (0.39) | CTSDACHEBCHEBCL2A1BID | |
| SCHEMBL6922300 | 0.82 | ACHE (0.44) | L3MBTL1ACHEBCHE | |
| SCHEMBL6922000 | 0.79 | ACHE (0.38) | CTSDACHEBCHE | |
| SCHEMBL12059079 | 0.77 | BCL2A1 (0.38) | L3MBTL1CTSDBCL2A1BIDLMNA | |
| SCHEMBL30723334 | 0.75 | BCHE (0.39) | L3MBTL1ACHEBCHELMNA | |
| SCHEMBL6922592 | 0.74 | CYP2D6 (0.40) | CTSDACHEBCHELMNA | |
| SCHEMBL6923330 | 0.74 | KDM4E (0.58) | L3MBTL1ACHEBCHELMNA | |
| SCHEMBL6921722 | 0.73 | GRM5 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | L3MBTL1 3622/4885CTSD 4089/4885ACHE 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.